The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.

Urology device developer NeoTract, which Teleflex purchased in 2017, is now under scrutiny for potential FCA violations. 

Jörn Aldag, who has over 20 years of leadership experience in the life sciences industry, including CEO of gene therapy pioneer uniQure, tells Scrip that the research carried at the world-class Italian research institute SR-Tiget.

The withdrawal of the EU filing for abicipar pegol will fuel speculation that Allergan parent AbbVie is indeed ditching the potential treatment for wet AMD. US regulators have already said they won't approve the drug.